Market Overview:
The global tetrabenazine API market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Huntington’s disease and rising demand for tetrabenazine tablets. Tetrabenazine is a drug used for the treatment of chorea associated with Huntington’s disease, Wilson’s disease, and other hyperkinetic movement disorders. It is also used off-label for the treatment of Tourette syndrome, obsessive-compulsive disorder (OCD), and bipolar disorder.
Product Definition:
Tetrabenazine is a drug approved for the treatment of hyperkinetic disorders like Huntingdon's disease and tardive dyskinesia. It functions by inhibiting vesicular monoamine transporter 2 (VMAT2) and blocking dopamine storage, leading to a decrease in dopamine levels.
Purity≥98%:
Purity 98% is a crystalline powder, which is soluble in water and ethanol. It has an odor similar to that of benzene. Purity 98% contains no additives or fillers and has not been treated with any chemical solvents. The product also contains no microorganisms, such as bacteria or fungi, and does not contain any toxic substances such as mercury or lead.
Purity
Purity 98% is a crystalline powder, which has been used as an intermediate in the production of several chemicals. It can be used to produce tetrabenazine (4-aminobenzoyl) acid phosphate, which has applications in pesticides and herbicides. The product also finds application as a feed additive for poultry and livestock.
Application Insights:
Tetrabenazine tablets were the largest revenue-generating segment in 2017. The product is used for the treatment of epilepsy with and without aura, migraine, Huntington’s disease and Down syndrome. Tetrabenazine is also used for preclinical testing of drugs that are intended to treat mental disorders as it reduces anxiety in mice.
The use of tetrabenazine has been declining due to availability of alternative therapies that are proven to be more effective than tetrabenazine such as sodium valproate, phenytoin sodium mononitrate and ethosuximide (Zarontin). However, growing usage for clinical trials on migraines may drive its demand over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers coupled with increasing awareness about new drug development is expected to drive the region’s growth over the forecast period. Asia Pacific is anticipated to witness fastest growth during the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China, India, and South Korea. Furthermore, growing investment by major pharmaceutical companies for R&D expansion will also have a positive impact on regional market development. Moreover, increasing cases of Parkinson’s disease are further fueling product demand in this region.
Latin America was estimated at USD X million in 2017 owing to high incidence rate associatedPD-1 inhibitors).
Growth Factors:
- Increasing prevalence of Huntington's disease (HD)
- Growing demand for novel therapies for the treatment of HD
- Rising awareness about the benefits of Tetrabenazine API therapy among physicians and patients
- Technological advancements in the field of Tetrabenazine API research and development
- increasing number of clinical studies evaluating the efficacy and safety profile of Tetrabenazine API
Scope Of The Report
Report Attributes
Report Details
Report Title
Tetrabenazine API Market Research Report
By Type
Purity≥98%, Purity<98%
By Application
Tetrabenazine Tablets, Others
By Companies
Piramal Enterprises Limited, Inke, Sun Pharmaceutical Industries Ltd., Synthetics China Co., Ltd, Hunan Huateng Pharmaceutical Co., Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
192
Number of Tables & Figures
135
Customization Available
Yes, the report can be customized as per your need.
Global Tetrabenazine API Market Report Segments:
The global Tetrabenazine API market is segmented on the basis of:
Types
Purity≥98%, Purity<98%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tetrabenazine Tablets, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Piramal Enterprises Limited
- Inke
- Sun Pharmaceutical Industries Ltd.
- Synthetics China Co., Ltd
- Hunan Huateng Pharmaceutical Co., Ltd.
Highlights of The Tetrabenazine API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity≥98%
- Purity<98%
- By Application:
- Tetrabenazine Tablets
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tetrabenazine API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tetrabenazine API is an oral medication used to treat schizophrenia. It works by blocking the action of dopamine in the brain.
Some of the key players operating in the tetrabenazine api market are Piramal Enterprises Limited, Inke, Sun Pharmaceutical Industries Ltd., Synthetics China Co., Ltd, Hunan Huateng Pharmaceutical Co., Ltd..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tetrabenazine API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tetrabenazine API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tetrabenazine API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tetrabenazine API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tetrabenazine API Market Size & Forecast, 2020-2028
4.5.1 Tetrabenazine API Market Size and Y-o-Y Growth
4.5.2 Tetrabenazine API Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Purity≥98%
5.2.2 Purity<98%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Tetrabenazine Tablets
6.2.2 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tetrabenazine API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tetrabenazine API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Purity≥98%
9.6.2 Purity<98%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Tetrabenazine Tablets
9.10.2 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Purity≥98%
10.6.2 Purity<98%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Tetrabenazine Tablets
10.10.2 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Purity≥98%
11.6.2 Purity<98%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Tetrabenazine Tablets
11.10.2 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Purity≥98%
12.6.2 Purity<98%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Tetrabenazine Tablets
12.10.2 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Purity≥98%
13.6.2 Purity<98%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Tetrabenazine Tablets
13.10.2 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tetrabenazine API Market: Competitive Dashboard
14.2 Global Tetrabenazine API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Piramal Enterprises Limited
14.3.2 Inke
14.3.3 Sun Pharmaceutical Industries Ltd.
14.3.4 Synthetics China Co., Ltd
14.3.5 Hunan Huateng Pharmaceutical Co., Ltd.
